New Enterprise Associates, Inc. (NEA)

New Enterprise Associates, Inc. (NEA) is a global venture capital firm focused on helping entrepreneurs build transformational businesses across multiple stages, sectors and geographies. With approximately $13 billion in committed capital, NEA invests in technology and healthcare companies at all stages in a company’s lifecycle, from seed stage through IPO. The firm's long track record of successful investing includes more than 190 portfolio company IPOs and more than 315 acquisitions since its founding in 1977. In the U.S., NEA has offices in Menlo Park, CA; Boston, MA; New York, NY; Chicago, IL; and the Washington, D.C. metropolitan area. In addition, New Enterprise Associates (India) Pvt. Ltd. has offices in Bangalore and Mumbai, India and New Enterprise Associates (Beijing), Ltd. has offices in Beijing and Shanghai, China. For additional information, visit



OrbiMed is a leading investment firm dedicated exclusively to the healthcare sector, with approximately $6 billion in assets under management as of September 30, 2012. With offices in New York City, San Francisco, Shanghai, Mumbai and Herzliya, OrbiMed invests across the spectrum of healthcare companies on a worldwide basis. OrbiMed seeks to be a capital provider of choice, bringing the global resources required to be an excellent long‐term partner for building world-class healthcare companies.

Aurora Funds

The Aurora Funds

The Aurora Funds is a family of venture capital funds committed to providing resources to help early stage healthcare and information technology companies reach their full potential.

Aurora's investment team has the experience, strategic relationships and capital to help companies accelerate their growth and gain a strong competitive advantage in their market space. Since its founding in 1994, Aurora has invested in over 60 portfolio companies, resulting in five IPOs and eight M&A transactions.

Osage University Partners

Osage University Partners

Osage University Partners is a venture capital fund that invests exclusively in spinouts derived from a network of 46 affiliated research institutions.

Nitroxyl Technology

Cardioxyl has developed proprietary expertise in the biology, physiology and chemistry of nitroxyl donors

View More

Our Mission

Cardioxyl's mission is to realize the potential of nitroxyl technology through the development of novel therapies that improve the health and quality of life of patients with serious cardiovascular disease.